Medicaid Work Requirements Threaten Billions in Drug Sales — WSJ

What happened

A 2025 budget law will require some adults who obtained Medicaid through the Affordable Care Act expansion to work or qualify for an exemption, starting in January. Health Management Associates estimates at least five million people could lose coverage, putting about $42 billion in drug sales at risk before manufacturer rebates.

Confirmed

Global impact / market context

If people lose Medicaid coverage, prescriptions they previously obtained through the program may decline, reducing drugmakers’ sales. The reported $42 billion is based on spending before manufacturer rebates, so it overstates the revenue actually at stake; HMA expects effects to begin in early 2027.

Analyst inference

HMA says a handful of brands accounted for 21% of the expansion-program drug spending at risk, including Humira and the named HIV, diabetes and weight-loss medicines. The article frames potential revenue losses as an industry concern alongside the approaching patent cliff, when patents expire and competition can grow.

Confirmed

What to watch

1. Watch whether the work-or-exemption rule starts as scheduled in January and how many people lose Medicaid coverage; HMA estimates at least five million could lose it. Confirmed
2. Track whether lawmakers reverse the cuts: Democrats say they want to act if they control both chambers, but a consultant sees low odds within two years. Proposed
3. Look for drugmakers’ sales effects in early 2027, especially for brands named by HMA; actual revenue exposure could be below $42 billion because rebates reduce spending. Analyst inference

Evidence

• Original source link unavailable